Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
01 Februar 2024 - 10:50PM
Business Wire
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a
biopharmaceutical company focused on discovering, developing, and
commercializing important new medicines to improve the lives of
people with cancer, today announced that it will report its fourth
quarter and full year 2023 financial results on Tuesday, February
6, 2024.
In connection with the earnings release, Deciphera’s management
team will host a live conference call and webcast at 8:00 AM ET on
Tuesday, February 6, 2024, to discuss the Company’s financial
results and provide a corporate update.
The conference call may be accessed via this link:
https://register.vevent.com/register/BI7a0bbbeb53864df9a854d959bbbae709
A live webcast of the conference call will be available in the
“Events and Presentations” page in the “Investors” section of the
Company’s website at
https://investors.deciphera.com/events-presentations. A replay will
be available on the Company’s website approximately two hours after
the conference call and will be available for 30 days following the
call.
About Deciphera Pharmaceuticals Deciphera is a
biopharmaceutical company focused on discovering, developing, and
commercializing important new medicines to improve the lives of
people with cancer. We are leveraging our proprietary
switch-control kinase inhibitor platform and deep expertise in
kinase biology to develop a broad portfolio of innovative
medicines. In addition to advancing multiple product candidates
from our platform in clinical studies, QINLOCK® is Deciphera’s
switch-control inhibitor for the treatment of fourth-line GIST.
QINLOCK is approved in Australia, Canada, China, the European
Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New
Zealand, Norway, Singapore, Switzerland, Taiwan, The United
Kingdom, and the United States. For more information, visit
www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240130118615/en/
Investor Relations: Maghan Meyers Argot Partners
Deciphera@argotpartners.com 212-600-1902
Media: David Rosen Argot Partners
David.Rosen@argotpartners.com 212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
Von Mai 2023 bis Mai 2024